Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

55.07
-0.1300-0.24%
Post-market: 54.50-0.5700-1.04%18:47 EDT
Volume:1.56M
Turnover:85.04M
Market Cap:5.26B
PE:-12.62
High:55.17
Open:54.93
Low:53.69
Close:55.20
52wk High:63.95
52wk Low:26.74
Shares:95.43M
Float Shares:89.89M
Volume Ratio:0.52
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3646
EPS(LYR):-4.3646
ROE:-51.76%
ROA:-32.58%
PB:9.03
PE(LYR):-12.62

Loading ...

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals Is Maintained at Outperform by Baird

Dow Jones
·
Mar 10

Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals price target raised to $97 from $63 at Baird

TIPRANKS
·
Mar 10

What's Going On With Biohaven Stock On Monday?

Benzinga_recent_news
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

Xenon Pharmaceuticals Up Over 45%, on Track for Record High Close -- Data Talk

Dow Jones
·
Mar 09

Xenon Pharmaceuticals rises 41.8%

TIPRANKS
·
Mar 09

Xenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results

Stock News
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

Xenon Pharmaceuticals Exec Says All Four Labeled Doses -10, 15, 20 and 25 Mg - Will Have Flat Pricing, Allowing Physicians to Start and Escalate Doses - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Azetukalner’s Data and Novel Mechanism “Demands” Optimized Pricing, Adding a Prior Therapy Was “Underpriced” - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Co Expects to Be “Extremely Well Positioned” for Launch of Azetukalner - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Shares Jump 16.5% Premarket After Co's Epilepsy Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Mar 09

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Reuters
·
Mar 09

Top Premarket Gainers

MT Newswires Live
·
Mar 09

Xenon Pharmaceuticals Inc - Azetukalner Demonstrates Consistent Safety Profile in X-Tole2 Study

THOMSON REUTERS
·
Mar 09

Xenon Announces Positive Topline Data From Phase 3 X-Tole2 Study of Azetukalner in Focal Onset Seizures (Fos)

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Inc: Anticipates Submitting New Drug Application for Azetukalner in Fos to U.S. FDA in Q3 2026

THOMSON REUTERS
·
Mar 09